Reduction of IOP in adult patients w/ open angle glaucoma or ocular HTN who are insufficiently responsive to topical monotherapy w/ β-blockers or prostaglandin analogues & require a combination therapy.
View Tapcom overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity. Patients w/ or history of bronchial asthma, bronchospasm, or severe COPD; poor-controlled cardiac failure, sinus bradycardia, 2nd- or 3rd-degree AV block, or cardiogenic shock.
Patients w/ right ventricular failure caused by pulmonary HTN; CHF; diabetic ketoacidosis or metabolic acidosis; poor-controlled diabetes; aphakia or pseudophakia; intraocular inflammation (iritis, uveitis). May be absorbed systemically & cause adverse drug reactions similar to those caused by systemic administration of a β-blocker. Pigmentation in iris & eyelid or hypertrichosis around the eyes may occur. Corneal epithelium disorder (superficial punctate keratitis, filamentary keratitis or corneal erosion) may occur during treatment. Closed angle glaucoma. Switch from a miotic may require refraction adjustment. Instill at least 5 min interval if other ophth drug is used. Remove contact lenses prior to administration & re-insert after at least 15 min. Contains benzalkonium Cl (closely monitor frequent or prolonged use in dry eye patients, or in conditions w/ compromised cornea). Not to be used to treat contact lens related irritation. Renal or hepatic impairment. Avoid driving or operating machinery if blurry vision develops. Pregnant, parturient women. Avoid administration to nursing mothers. Not recommended in childn & adolescents <18 yr. Infants (low birth wt) & neonates. Elderly.
Sign Out
